Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard vs Low Dose Ticagrelor in Diabetic STEMI
NCT05831462Phase 2Unknown
- Sponsor
- Assiut University
- Start
- Jun 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised trial of ticagrelor in ST elevation myocardial infarction (STEMI) (2 arms), sponsored by Assiut University. Primary endpoints: Primary efficacy endpoint at 12 months and Primary safety endpoint at 12 months. Status: unknown.
02
Drugs
ticagrelor
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT05831462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05831462.